Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | recruiting | Phase 2 | 88 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06736704 | SNV4818 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 320 | Pikavation Therapeutics, Inc.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07466160 | A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07018622 | Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity(DAPA-ARMOR) | recruiting | Phase 2 | 46 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | recruiting | Phase 1 / Phase 2 | 401 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07464457 | Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors(NEOPRO-SIT) | recruiting | N/A | 125 | Priv.-Doz. Dr. med. Philipp LenzOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04723810 | TumorGlow Intraoperative Molecular Imaging (IMI) | recruiting | Phase 1 / Phase 2 | 500 | University of PennsylvaniaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07069062 | A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 261 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05661201 | NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | recruiting | Phase 1 | 24 | Georgetown UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06171750 | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors(ANCHOR) | recruiting | Phase 1 | 97 | Ankyra Therapeutics, IncINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02474160 | Collection and Storage of Tissue and Blood Samples From Patients With Cancer | recruiting | — | 5,000 | National Cancer Institute LAOUNKNOWN | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06667960 | Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 255 | Salubris Biotherapeutics IncINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 48 | University of California, San DiegoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05166694 | Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions | recruiting | N/A | 1,300 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06424665 | A Study of FZ-AD005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 162 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07028281 | A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors | recruiting | Phase 2 | 120 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07304128 | A Study of PLB-002 in Advanced Solid Tumors | recruiting | Phase 1 | 100 | Primelink BioTherapeitics(ShenZhen) LimitedINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446816 | A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181 | recruiting | Phase 1 | 24 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06612645 | Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors(CMD03) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07269080 | STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study(STM-06) | recruiting | Phase 1 | 28 | University of Illinois at ChicagoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04469530 | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors(AflacST1903) | recruiting | Phase 2 | 55 | Emory UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06410209 | A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | recruiting | Phase 2 | 190 | Children's Oncology GroupNETWORK | 2 | Feb 27, 2026 | clinicaltrials |
| NCT07279428 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06521554 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | recruiting | Phase 1 | 200 | Nuvalent Inc.INDUSTRY | 3 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07108114 | SLV-324 Treatment of Metastatic Solid Tumors | recruiting | Phase 1 | 70 | Solve TherapeuticsINDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07123103 | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 150 | ExelixisINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414316 | A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. | recruiting | Early Phase 1 | 10 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05103683 | First in Human Study of TORL-1-23 in Participants With Advanced Cancer | recruiting | Phase 1 | 90 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT06358677 | Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors(FACE) | recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06973863 | A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 40 | PharmaEngineINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT07036133 | Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment(SPI-FOL-102) | recruiting | Phase 1 | 24 | Acrotech Biopharma Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07328217 | A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 203 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06634849 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). | recruiting | Phase 1 / Phase 2 | 30 | Pathios Therapeutics Pty LtdINDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05620017 | Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection | recruiting | Phase 1 | 182 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06534190 | CD8 PET Imaging in Metastatic Solid Tumours | recruiting | Phase 2 | 30 | University Medical Center GroningenOTHER | 3 | Feb 9, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04932525 | Gustave Roussy Cancer Profiling(STING) | recruiting | N/A | 20,000 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07392736 | A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 228 | Advenchen Laboratories, LLCINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03465592 | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | recruiting | Phase 1 / Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05701527 | A Study of EBC-129 in Advanced Solid Tumours | recruiting | Phase 1 | 98 | EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesOTHER_GOV | 3 | Feb 5, 2026 | clinicaltrials |
| NCT07359066 | An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 210 | Shanghai SciBrunch Therapeutics Co., Ltd.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05892718 | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | recruiting | Phase 1 | 80 | FBD Biologics LimitedINDUSTRY | 3 | Feb 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2026source: clinicaltrials